Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Venetoclax + Pembrolizumab in First-Line High PD-L1 NSCLC
NCT04274907Phase 1Terminated
- Sponsor
- AbbVie Inc.
- Start
- Jun 2020
- Primary completion
- Feb 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of venetoclax in non-small cell lung cancer (NSCLC) (3 arms), sponsored by AbbVie Inc. Primary endpoints: Dose-Limiting Toxicities up to 28 Days and Change in the Sum of the Longest Diameter. Started Jun 2020; status: terminated.
02
Drugs
venetoclax
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04274907.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04274907.